{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-179012","form_type":"8-K","ticker":"PSTV","cik":"0001095981","company_name":"PLUS THERAPEUTICS, INC.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.327260+00:00","generated_at":"2026-05-17T14:15:29.270538+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"confidence":"high","headline":"Plus Therapeutics shareholders approve reverse stock split authorization and up to $50M issuance to Lincoln Park","bullets":["All six director nominees were elected to the board for a term expiring at the 2026 annual meeting.","Approved potential issuance of up to $50M common stock plus $1M commitment fee to Lincoln Park Capital Fund.","Board authorized to effect a reverse stock split at a ratio between 1:2 and 1:250 within 12 months.","Advisory vote on executive compensation passed with 16,714,842 votes for and 858,028 against.","Fifth amendment and restatement of the 2020 Stock Incentive Plan was approved by stockholders."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-179012","json":"https://secwatch.observer/filing/0001193125-25-179012.json","markdown":"https://secwatch.observer/filing/0001193125-25-179012.md","text":"https://secwatch.observer/filing/0001193125-25-179012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1095981/000119312525179012/0001193125-25-179012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1095981/000119312525179012/d71976d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:15:29.270538+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}